These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32880853)

  • 21. Remdesivir treatment does not reduce viral titers in patients with COVID-19.
    Faghihi I; Yan VC
    Antimicrob Agents Chemother; 2024 Aug; 68(8):e0085624. PubMed ID: 39023261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit.
    Sun D
    AAPS J; 2020 May; 22(4):77. PubMed ID: 32458279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COVID-19: Rescue by transcriptional inhibition.
    Shilatifard A
    Sci Adv; 2020 Jul; 6(27):. PubMed ID: 32937442
    [No Abstract]   [Full Text] [Related]  

  • 24. Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients.
    Weinbergerova B; Mayer J; Kabut T; Hrabovsky S; Prochazkova J; Kral Z; Herout V; Pacasova R; Zdrazilova-Dubska L; Husa P; Bednar P; Ruzek D; Lengerova M
    Hematol Oncol; 2021 Dec; 39(5):715-720. PubMed ID: 34396566
    [No Abstract]   [Full Text] [Related]  

  • 25. Remdesivir: A giant step, or a tiptoe?
    Dickinson GM
    Clin Dermatol; 2020; 38(6):773-774. PubMed ID: 32405143
    [No Abstract]   [Full Text] [Related]  

  • 26. Comment on: Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.
    Barone F; Giacomelli A; Casalini G; Corbellino M; Lai A; Gori A; Antinori S
    J Antimicrob Chemother; 2024 Sep; 79(9):2400-2402. PubMed ID: 39073825
    [No Abstract]   [Full Text] [Related]  

  • 27. Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication.
    Bravo JPK; Dangerfield TL; Taylor DW; Johnson KA
    Mol Cell; 2021 Apr; 81(7):1548-1552.e4. PubMed ID: 33631104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Potential Antiviral Treatment for COVID-19: Remdesivir.
    O'Malley PA
    Clin Nurse Spec; 2020; 34(6):257-260. PubMed ID: 33009111
    [No Abstract]   [Full Text] [Related]  

  • 29. Audio Interview: Covid-19 Vaccination and the Omicron Variant.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 Dec; 385(27):e102. PubMed ID: 34965346
    [No Abstract]   [Full Text] [Related]  

  • 30. Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis.
    Focosi D; Maggi F; McConnell S; Casadevall A
    Antiviral Res; 2022 Feb; 198():105247. PubMed ID: 35033572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concentrations of remdesivir and GS-441524 in human milk from lactating individuals diagnosed with COVID-19.
    Bertrand K; Sepulveda Y; Spiegel BJ; Best BM; Suhandynata R; Rossi S; Chambers CD; Momper JD
    Pediatr Res; 2024 Jul; 96(2):269-272. PubMed ID: 38347172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Computational and theoretical exploration for clinical suitability of Remdesivir drug to SARS-CoV-2.
    Nayeem SM; Sohail EM; Sudhir GP; Reddy MS
    Eur J Pharmacol; 2021 Jan; 890():173642. PubMed ID: 33065096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Remdesivir and Potential Interactions With Psychotropic Medications: A COVID-19 Perspective.
    Mansuri Z; Shah B; Zafar MK; Jolly T; Jain S
    Prim Care Companion CNS Disord; 2020 May; 22(3):. PubMed ID: 32470232
    [No Abstract]   [Full Text] [Related]  

  • 34. [Chloroquine as a possible treatment for COVID-19].
    Coumou J; de Vries PJ
    Ned Tijdschr Geneeskd; 2020 Mar; 164():. PubMed ID: 32391999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coronavirus Disease (COVID-19) Pandemic: A Race Against Time.
    Banerjee AK; Arora N
    Curr Top Med Chem; 2020; 20(16):1434-1437. PubMed ID: 32282303
    [No Abstract]   [Full Text] [Related]  

  • 36. The Challenges Ahead With Monoclonal Antibodies: From Authorization to Access.
    Goldstein RH; Walensky RP
    JAMA; 2020 Dec; 324(21):2151-2152. PubMed ID: 33175110
    [No Abstract]   [Full Text] [Related]  

  • 37. A 10-Year-old Girl With Late Acute Lymphoblastic Leukemia Recurrence Diagnosed With COVID-19 and Treated With Remdesivir.
    Gadzińska J; Kuchar E; Matysiak M; Wanke-Rytt M; Kloc M; Kubiak JZ
    J Pediatr Hematol Oncol; 2022 Mar; 44(2):e537-e538. PubMed ID: 33885040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neonates With SARS-CoV-2 Infection and Pulmonary Disease Safely Treated With Remdesivir.
    Saikia B; Tang J; Robinson S; Nichani S; Lawman KB; Katre M; Bandi S
    Pediatr Infect Dis J; 2021 May; 40(5):e194-e196. PubMed ID: 33847299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Remdesivir in The Treatment of COVID-19.
    Rosenberg K
    Am J Nurs; 2021 Jan; 121(1):55. PubMed ID: 33350698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SARS-CoV-2 Antiviral Prescribing Gaps Among Nonhospitalized High-Risk Adults.
    Levy ME; Burrows E; Chilunda V; Pawloski PA; Heaton PR; Grzymski J; Goldman JD; McEwen LM; Wyman D; Dei Rossi A; Dai H; Isaksson M; Washington NL; Basler T; Tsan K; Nguyen J; Ramirez J; Sandoval E; Lee W; Lu J; Luo S
    Clin Infect Dis; 2024 Jun; 78(6):1531-1535. PubMed ID: 38170452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.